TransCode Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:RNAZ) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 13.19 M8.27 M5.23 M162.4 M157.16 M Total liabilities 2.9 M2.12 M3.8 M10.52 M12.64 M Total equity 10.29 M6.15 M1.43 M10.34 M1.25 M Total liabilities & shareholders' equities 13.19 M8.27 M5.23 M162.4 M157.16 M Total debt ————— Net debt —————

News

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud

TransCode licenses bladder cancer therapy platform from Unleash

TransCode Therapeutics stock soars after promising glioblastoma study

TransCode Therapeutics appoints Jack E. Stover to board of directors

TransCode and Quantum Leap to test cancer therapy in phase 2a trial

TransCode Therapeutics appoints Michel Janicot as development officer

Transcode Therapeutics amends preferred stock terms following shareholder approval

TransCode reports positive safety data from TTX-MC138 phase 1a trial

Hong Kong healthtech stocks fall on profit-taking, Microsoft healthcare push

TransCode Therapeutics stock soars after Polynoma acquisition

What's Going On With TransCode Therapeutics Stock Wednesday? - TransCode Therapeutics (NASDAQ:RNAZ), CK Life Sciences Intl (OTC:CKLSF)